Last updated: September 2, 2026
Defibrotide sodium, marketed as Defitelio in the United States and Defitelio or Defitelio-related products in Europe, is a specialized therapy for severe hepatic veno-occlusive disease, also called sinusoidal obstruction syndrome, after hematopoietic stem-cell transplantation. Jazz Pharmaceuticals owns the commercial rights in major markets through its acquisition of Gentium.
The product has a narrow indication, limited competition and high clinical value in a rare transplant complication. Its commercial ceiling is constrained by the small patient population, declining incidence of severe veno-occlusive disease, transplant-center concentration and the loss of U.S. orphan exclusivity in 2023. The primary remaining barriers to competition are product complexity, limited commercial scale and the difficulty of conducting the clinical and manufacturing work required for a generic version of a heterogeneous nucleic-acid mixture.
What is defibrotide sodium and what does it treat?
Defibrotide sodium is a polydisperse mixture of predominantly single-stranded oligodeoxyribonucleotides derived from porcine mucosal DNA. It is not a conventional single-molecule small drug and is not a monoclonal antibody or other biologic.
The FDA approved Defitelio in March 2016 for the treatment of adult and pediatric patients at least one month old with hepatic veno-occlusive disease with renal or pulmonary dysfunction following hematopoietic stem-cell transplantation.[1] The European Commission granted marketing authorization in October 2013 for treatment of severe hepatic veno-occlusive disease after transplantation therapy.[2]
| Attribute |
Defibrotide sodium |
| Brand |
Defitelio |
| Active ingredient |
Defibrotide sodium |
| Drug class |
Polydisperse oligonucleotide mixture |
| Primary disease |
Severe hepatic veno-occlusive disease/sinusoidal obstruction syndrome |
| Treatment setting |
Post-hematopoietic stem-cell transplantation |
| U.S. approval |
March 2016 |
| EU authorization |
October 2013 |
| U.S. sponsor |
Jazz Pharmaceuticals |
| Original developer |
Gentium S.p.A. |
| Administration |
Intravenous infusion |
| Standard U.S. regimen |
6.25 mg/kg every six hours for at least 21 days, continued until resolution or discharge |
The drug is administered in specialized transplant hospitals. That limits prescribing leakage into general oncology channels and concentrates purchasing power among a small number of institutions and hospital systems.
How large is the defibrotide sodium market?
The addressable market is small by pharmaceutical standards but economically attractive because Defitelio is used in a life-threatening complication with few treatment alternatives.
Market demand is determined by four variables:
- The number of allogeneic and autologous transplants performed.
- The incidence of hepatic veno-occlusive disease.
- The percentage of cases that progress to severe disease.
- The proportion of eligible patients treated with defibrotide.
The incidence of severe veno-occlusive disease has been reduced by improved transplant protocols, ursodeoxycholic acid prophylaxis, better conditioning strategies and earlier diagnosis. Reduced-intensity conditioning and improved supportive care also affect the number of patients who progress to severe organ dysfunction.
At the same time, transplant volumes have generally expanded over the long term. This offsets part of the decline in disease incidence, but does not create the growth profile associated with broad oncology products.
Geographic market structure
The United States and Europe represent the principal commercial markets. Sales are concentrated in:
- The United States
- Germany
- France
- Italy
- Spain
- The United Kingdom
- Other European transplant centers
- Selected markets in Asia and the Middle East
The product is generally distributed through hospital, specialty-pharmacy and transplant-center channels. Treatment decisions are made by transplant physicians and pediatric specialists rather than community oncologists.
What is the financial trajectory for Defitelio?
Jazz Pharmaceuticals reports Defitelio within its commercial product portfolio. The product has generated annual revenue in the low-to-mid hundreds of millions of dollars, with the general trajectory shifting from growth after launch to maturity and gradual decline.
The key financial pattern is:
| Period |
Financial position |
| 2013-2015 |
European commercial buildout before U.S. approval |
| 2016 |
U.S. approval expanded the addressable market |
| 2017-2020 |
Revenue growth as U.S. transplant-center adoption increased |
| 2021-2023 |
Mature-product phase with pressure from lower disease incidence and exclusivity loss |
| 2024 onward |
Higher exposure to generic entry, tender pricing and market contraction |
Public Jazz filings indicate that Defitelio has generally contributed approximately $150 million to $190 million in annual product sales during its mature commercial period, although year-to-year performance has varied with transplant activity, patient mix, international pricing and inventory timing.[3][4]
Defitelio is strategically important but financially modest relative to Jazz's leading products. Jazz's largest revenue drivers include Xyrem, Xywav, Epidiolex/Epidyolex and Rylaze. Defitelio therefore has limited ability to alter consolidated company performance unless competition causes a sharp decline or the product is bundled into a broader hospital-product strategy.
What drives Defitelio revenue?
Revenue is most sensitive to:
- Severe veno-occlusive disease incidence
- Annual hematopoietic stem-cell transplantation volume
- Diagnosis and treatment timing
- Number of treatment days per patient
- U.S. hospital purchasing contracts
- International reimbursement and tender pricing
- Use in pediatric transplant patients
- Generic or alternative-product entry
The treatment course is expensive because patients receive repeated intravenous doses for a minimum of 21 days. A standard 6.25 mg/kg dose administered every six hours creates high per-patient drug consumption, especially in larger adults.
When does defibrotide sodium lose exclusivity?
U.S. orphan-drug exclusivity expired in March 2023, seven years after FDA approval. Orphan exclusivity prevents FDA approval of the same drug for the same indication during the exclusivity period, subject to statutory exceptions.[5]
The European orphan designation was granted in 2004, with marketing authorization in 2013. European orphan-market protection generally runs for 10 years from authorization, with possible extension for pediatric compliance. The core European orphan period therefore reached maturity around 2023-2024, depending on the applicable regulatory extension and national implementation.[2]
The principal U.S. exclusivity milestones are:
| Exclusivity or protection |
Date or status |
| FDA approval |
March 30, 2016 |
| U.S. orphan-drug exclusivity |
Generally expired March 30, 2023 |
| U.S. pediatric exclusivity |
No material separate period is identified in the standard FDA approval record |
| EU marketing authorization |
October 2013 |
| EU orphan protection |
Reached the end of its standard term around 2023-2024 |
| Current commercial risk |
Generic or competing defibrotide product development |
Loss of orphan exclusivity does not automatically produce generic competition. A competitor still needs an approvable regulatory pathway, a manufacturable product, reliable analytical characterization and sufficient commercial incentive.
What patents protect defibrotide sodium?
The main protection historically associated with defibrotide has included formulation, therapeutic-use and manufacturing claims rather than a simple composition-of-matter patent covering a conventional defined molecule.
Patent protection is more difficult to evaluate than for a single-molecule drug because defibrotide is a complex mixture with defined source material, molecular-weight distribution, manufacturing controls and biological activity. The relevant intellectual-property categories include:
- Methods for treating hepatic veno-occlusive disease
- Use in transplant-related endothelial injury
- Dosing and administration regimens
- Pharmaceutical formulations
- Purification and manufacturing processes
- Quality-control specifications for the oligonucleotide mixture
- Use in renal, pulmonary or other endothelial disorders
A listed patent, if present, would not necessarily block every competing product. A competitor could challenge validity, design around process claims or pursue a regulatory route that addresses listed patents through certification.
The economic importance of formulation and manufacturing patents is higher than the value of a conventional compound patent in this case. The active ingredient is not readily replicated by synthesizing one defined chemical entity.
What is the Orange Book status of Defitelio?
Defitelio is approved under NDA 208114. The FDA Orange Book is the relevant source for current U.S. patent listings, exclusivity and approved product information.[6]
The central commercial point is that the expiration of orphan exclusivity removed the strongest regulatory barrier to competition. Any remaining listed patents, if enforceable and relevant to an entrant's proposed product, would create a narrower barrier than the former orphan exclusivity period.
The Orange Book does not resolve all competitive risk. It does not fully capture:
- Trade-secret manufacturing controls
- Unlisted process know-how
- Supplier qualification requirements
- European patent rights
- Data packages needed for a complex mixture
- Hospital adoption barriers
- Clinical evidence expectations for severe veno-occlusive disease
Are there Paragraph IV challenges to Defitelio?
No major publicly established Paragraph IV litigation has materially altered the Defitelio market in the commonly reported U.S. pharmaceutical litigation record through the latest publicly available company disclosures reviewed.
That does not eliminate future risk. A prospective ANDA applicant could file a Paragraph IV certification against any relevant Orange Book-listed patent. Litigation would then determine whether the patent is valid, infringed or enforceable. If no listed patent blocks approval, an ANDA applicant could pursue a Paragraph III certification or a different pathway.
A Paragraph IV challenge would be commercially difficult for a product with a limited patient population. The entrant would need to justify:
- The cost of developing a complex defibrotide product
- The ability to satisfy FDA chemistry, manufacturing and controls requirements
- The expected discount needed to win hospital contracts
- The likelihood of physician substitution
- The cost of post-launch pharmacovigilance
- The risk of manufacturing inconsistency
How strong is the patent estate for defibrotide sodium?
The estate is better characterized as a moderate commercial barrier than as a dominant blocking estate.
Strengths
- Defibrotide is a complex biological-derived oligonucleotide mixture.
- Manufacturing consistency is difficult to replicate.
- The product has a narrow but serious clinical indication.
- Transplant physicians may resist substitution without strong comparability data.
- Hospital formularies value reliable supply in urgent treatment settings.
- Process know-how may be more important than publicly visible patent claims.
Weaknesses
- U.S. orphan exclusivity has expired.
- The product is an established therapy with a defined label.
- The addressable patient population is small.
- Revenue may not support multiple full-scale competitors.
- A competitor could target price-sensitive hospital systems.
- Method-of-use claims may be vulnerable to validity or scope challenges.
The commercial moat is therefore based on regulatory complexity, manufacturing expertise, brand reliability and clinical familiarity more than on a single long-lived patent.
What formulation and manufacturing barriers affect generic entry?
Defibrotide is administered intravenously and requires a sterile, injectable presentation. Manufacturing controls are central to product quality.
An entrant would need to demonstrate control over:
- Source biological material
- Depolymerization or processing steps
- Molecular-weight distribution
- Sequence distribution
- Purity and impurity profile
- Endotoxin and microbial controls
- Sterility
- Stability
- Container-closure integrity
- Batch-to-batch biological activity
These requirements create a barrier that is materially higher than for a standard immediate-release tablet. The regulatory question is not only whether the active ingredient has the same name. It is whether the proposed product is sufficiently comparable in composition, quality and clinical performance.
The most likely entrant would be a company with injectable manufacturing capacity, oncology or transplant distribution and experience with complex biological-derived products.
Is biosimilar competition relevant to defibrotide sodium?
No. Defibrotide is not regulated as a monoclonal antibody or other reference biologic for biosimilar purposes. The more relevant competitive routes are:
- Abbreviated new drug application
- Hybrid or full application, depending on jurisdiction
- Complex-generic development
- A product-specific application supported by analytical and clinical data
The regulatory pathway may differ by country because the active ingredient is a mixture and national authorities may apply different standards to comparability.
Which companies are challenging the Defitelio market?
No competitor has established a broad, branded alternative with equivalent regulatory positioning for severe hepatic veno-occlusive disease after hematopoietic stem-cell transplantation.
Competitive pressure comes from three sources:
- Generic-development companies evaluating defibrotide.
- Hospital treatment protocols that reduce disease incidence.
- Supportive-care and prophylactic strategies that lower the number of severe cases.
Defibrotide remains the principal approved drug option for the labeled severe disease population in the United States and Europe. Competition is therefore more likely to emerge through a generic or regional equivalent than through a directly competing branded therapy.
What patent litigation and settlement risks affect Defitelio?
There is no widely reported major settlement agreement involving a U.S. Defitelio Paragraph IV dispute that currently defines the market.
If a future entrant files an ANDA, possible outcomes include:
| Scenario |
Commercial effect |
| No patent litigation |
Earliest approval after regulatory review |
| Paragraph IV litigation |
Potential 30-month stay and delayed launch |
| Settlement with delayed entry |
Controlled erosion date negotiated with Jazz |
| At-risk launch |
Potential damages and injunction exposure |
| Limited-label entry |
Reduced initial market penetration |
| Process-based competition |
Possible approval without direct infringement of use claims |
Settlement value would depend on the strength of any remaining listed patents, expected approval timing, manufacturing readiness and the small size of the market.
What generic launch scenarios exist for defibrotide?
Scenario 1: No near-term generic
Jazz retains most of the market because the product is difficult to manufacture and the revenue opportunity is too small for a large generic investment.
Scenario 2: One specialized entrant
A single injectable or complex-generic manufacturer enters with a discount of approximately 20% to 40%. Hospital tenders shift a portion of volume, while transplant centers continue using Defitelio for high-risk or pediatric cases.
Scenario 3: Multiple entrants
Two or more suppliers compete on price. Net pricing declines sharply, hospital purchasing becomes tender-driven and Jazz revenue contracts faster than patient volume.
Scenario 4: Regional competition
A competitor launches outside the United States or in selected European markets first. The effect is concentrated in countries with centralized reimbursement and tender procurement.
The most probable commercial pattern is gradual erosion rather than an immediate collapse. The indication is too specialized for automatic substitution across all hospitals.
How does Defitelio compare with competing drug assets?
| Factor |
Defitelio |
Broad oncology drug |
Conventional generic |
| Patient population |
Very small |
Large or moderate |
Often large |
| Competition |
Limited |
Usually substantial |
Often intense |
| Manufacturing |
Complex mixture, sterile injectable |
Varies |
Usually standardized |
| Prescribing channel |
Transplant centers |
Oncology networks |
Broad pharmacy or hospital |
| Price sensitivity |
High at hospital level |
Depends on therapy |
Very high |
| Biosimilar risk |
Not applicable |
May apply |
Not applicable |
| Patent dependence |
Moderate |
Often high |
Patent-expiry driven |
| Revenue durability |
Moderate, niche |
Variable |
Usually low after entry |
Defitelio has a stronger clinical position than its revenue scale suggests, but a weaker long-term exclusivity profile than a patented novel oncology molecule.
What is Jazz Pharmaceuticals' financial exposure?
Defitelio's contribution to Jazz is meaningful at the product level but limited at the company level. The product does not carry the same revenue concentration risk as Xyrem or Xywav, and a decline in Defitelio sales would not normally determine Jazz's consolidated valuation.
The principal financial risks are:
- U.S. generic entry after orphan exclusivity expiration
- European pricing and reimbursement reductions
- Declining severe disease incidence
- Hospital inventory reductions
- Manufacturing interruptions
- Increased use of prophylaxis and early intervention
- A shift from branded procurement to tender purchasing
The main upside is sustained treatment penetration in pediatric and adult transplant centers, coupled with the absence of a technically credible generic entrant.
Key Takeaways
- Defibrotide sodium is a specialized intravenous therapy for severe hepatic veno-occlusive disease after stem-cell transplantation.
- Jazz Pharmaceuticals owns the principal commercial position through its acquisition of Gentium.
- U.S. orphan exclusivity expired in March 2023.
- The product's commercial protection now depends more on manufacturing complexity, clinical familiarity and distribution than on regulatory exclusivity.
- Annual Defitelio revenue has been in the approximate $150 million to $190 million range during its mature period.
- No major publicly established Paragraph IV litigation or settlement currently defines the market.
- Biosimilar competition is not applicable.
- The main threat is a complex-generic or regional equivalent able to reproduce the product's quality profile at a lower price.
- Defitelio is financially meaningful as a niche asset but is unlikely to drive Jazz Pharmaceuticals' consolidated trajectory.
- Generic erosion is more likely to be gradual than immediate because treatment is concentrated in transplant centers and product manufacturing is difficult.
FAQs
Is defibrotide sodium still patent protected in the United States?
The major U.S. orphan exclusivity period expired in March 2023. Any remaining protection depends on current Orange Book listings, patent scope and enforceability rather than orphan status alone.
Can defibrotide sodium be substituted automatically with a generic?
Automatic substitution would depend on FDA approval, state substitution law, hospital formulary policy and the approved product's therapeutic-equivalence designation. Complex manufacturing may make institutional substitution more cautious.
Is Defitelio a biologic drug?
Defitelio is a polydisperse oligonucleotide mixture derived from porcine mucosal DNA. It is not a monoclonal antibody and is not typically analyzed through the biosimilar framework used for biologic medicines.
Why is the defibrotide market commercially attractive despite its small size?
The drug treats a life-threatening condition with limited alternatives, supports high per-patient treatment revenue and has concentrated specialist demand. Those factors can support pricing even though the patient population is small.
What would cause Defitelio sales to fall fastest?
The fastest decline would result from a technically reliable generic entering multiple major markets, combined with hospital tender discounts and lower severe veno-occlusive disease incidence.
References
-
U.S. Food and Drug Administration. (2016). Defitelio prescribing information. FDA.
-
European Medicines Agency. (2013). Defitelio: EPAR product information. EMA.
-
Jazz Pharmaceuticals plc. (2022). Annual report on Form 10-K for the fiscal year ended December 31, 2022. U.S. Securities and Exchange Commission.
-
Jazz Pharmaceuticals plc. (2023). Annual report on Form 10-K for the fiscal year ended December 31, 2023. U.S. Securities and Exchange Commission.
-
U.S. Food and Drug Administration. (2023). Orphan drug designation and exclusivity. FDA.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book. FDA.
